NewslettersHuman Immunology News Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair Proficient Colorectal Cancer By Jamie Kang - May 27, 2025 0 159 Researchers investigated whether LAG-3/PD-1 inhibition would improve clinical outcomes in a mismatch repair proficient colorectal cancer subset. [Clinical Cancer Research] Abstract